参考文献/References:
[1] RICHARDSON D L,ESKANDER R N,MALLEY D M.Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance:A narrative review[J].JAMA Oncol,2023,9(6):851-859.
[2] SMITH M,POTHURI B.Appropriate selection of PARP inhibitors in ovarian cancer[J].Curr Treat Options Oncol,2022,23(6):887-903.
[3] 许静,李霞.化瘀利水方联合腹腔热灌注化疗治疗原发性卵巢癌伴癌性腹水疗效观察[J].陕西中医,2023,44(9):1202-1204.
[4] MA L,LIU W,LI M.circ-0061140 contributes to ovarian cancer progression by targeting miR-761/LETM1 signaling[J].Biochem Genet,2023,61(2):628-650.
[5] 陈隆,张玉富.胶质瘤中circular RNA PRKCI的表达及预后相关影响因素研究[J].陕西医学杂志,2021,50(11):1449-1451.
[6] WANG H,ZHANG X,QIAO L,et al.circRNA circ-0000554 promotes ovarian cancer invasion and proliferation by regulating miR-567[J].Environ Sci Pollut Res Int,2022,29(13):19072-19080.
[7] NAJAFI S.The emerging roles and potential applications of circular RNAs in ovarian cancer:A comprehensive review[J].J Cancer Res Clin Oncol,2023,149(5):2211-2234.
[8] 刘少璇,李佳,刘芳媛,等.基于“亢害承制”理论辨析卵巢癌因机证治[J].陕西中医,2022,43(7):925-928.
[9] 徐梓凡,郑昊涵,谢田华,等.环状RNA功能及与眼科相关疾病关系研究进展[J].陕西医学杂志,2023,52(5):626-629.
[10] FU L,ZHANG D,YI N,et al.circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression [J].Hum Cell,2022,35(5):1560-1576.
[11] ZHENG Y,LI Z,YANG S,et al.circEXOC6B suppresses the proliferation and motility and sensitizes ovarian cancer cells to paclitaxel through miR-376c-3p/FOXO3 axis[J].Cancer Biother Radiopharm,2022,37(9):802-814.
[12] SUN N,LIU S,CHEN A.Diagnostic value of non-coding RNAs in ovarian cancer[J].J Obstet Gynaecol,2022,42(8):3416-3423.
[13] HUANG C,QIN L,CHEN S,et al.circSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression[J].Anticancer Drugs,2023,34(3):395-404.
[14] LI X,JIANG X,LU J,et al.circCERS6 suppresses the development of epithelial ovarian cancer through mediating miR-630/RASSF8[J].Biochem Genet,2022,60(6):2611-2629.
[15] HUANG X,LUO Y,LI X.circ-0072995 promotes ovarian cancer progression through regulating miR-122-5p/SLC1A5 axis[J].Biochem Genet,2022,60(1):153-172.
[16] YING H,ZHAO R,YU Q,et al.circATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis[J].Drug Dev Res,2022,83(2):512-524.
[17] WU Y,ZHOU J,LI Y,et al.Hsa-circ-0001445 works as a cancer suppressor via miR-576-5p/SFRP1 axis regulation in ovarian cancer[J].Cancer Med,2023,12(5):5736-5750.
[18] FU Y,LI Y,WANG X,et al.Overexpression of miR-425-5p is associated with poor prognosis and tumor progression in non-small cell lung cancer[J].Cancer Biomark,2020,27(2):147-156.
[19] LIU D,ZHANG H,CUI M,et al.Hsa-miR-425-5p promotes tumor growth and metastasis by activating the CTNND1-mediated β-catenin pathway and EMT in colorectal cancer[J].Cell Cycle,2020,19(15):1917-1927.
[20] ZHANG L F,ZHANG J G,ZHOU H,et al.microRNA-425-5p promotes breast cancer cell growth by inducing PI3K/AKT signaling[J].Kaohsiung J Med Sci,2020,36(4):250-256.
[21] ZHAO Y,YUAN D,ZHU D,et al.lncRNA-MSC-AS1 inhibits the ovarian cancer progression by targeting miR-425-5p[J].J Ovarian Res,2021,14(1):109.
[22] BI X,LV X,LIU D,et al.METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway[J].Cancer Gene Ther,2021,28(3-4):335-349.
[23] WU Z,GUO J,ZHANG Y,et al.miR-425-5p accelerated the proliferation,migration,and invasion of ovarian cancer cells via targeting AFF4[J].J Ovarian Res,2021,14(1): 138.
[24] XIAO S,ZHU H,LUO J,et al.miR-425-5p is associated with poor prognosis in patients with breast cancer and promotes cancer cell progression by targeting PTEN[J].Oncol Rep,2019,42(6): 2550-2560.
[25] ZHOU J S,YANG Z S,CHENG S Y,et al.miRNA-425-5p enhances lung cancer growth via the PTEN/PI3K/AKT signaling axis[J].BMC Pulm Med,2020,20(1): 223.